Hikma intros Regadenoson injection in prefilled syringe
Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress.
Hikma is offering Regadenoson injection, in prefilled syringe form in a 0.4mg/5ml dose.
Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress.
[Read more: Hikma to acquire Custopharm]
Regadenoson injection, 0.4mg/5ml had a market value of approximately $668 million in the 12 months ending February 2023, according to IQVIA.